Artelo Biosciences Inc Stock Price, News & Analysis

Artelo Biosciences (NASDAQ: ARTL) has received Clinical Trial Authorization (CTA) in the UK for its Cancer Appetite Recovery Study (CAReS) aimed at treating cancer-related anorexia. The Phase 1/2 trial will evaluate the efficacy and safety of synthetic cannabinoid ART27.13, targeting a market of over $2 billion. With a recruitment goal of 43 patients, the company plans to initiate enrollment before year-end 2020, despite operational challenges posed by the Covid-19 pandemic. The trial addresses a significant unmet need, as cancer-related anorexia affects over 60% of advanced cancer patients.

Artelo Biosciences (NASDAQ:ARTL), a biopharmaceutical company, will present at the Virtual Fall Investor Summit from November 16-18, 2020. CEO Gregory D. Gorgas is scheduled to speak on November 18 at 11:30 a.m. ET. The presentation will be available for live streaming and replay. Attendees can schedule one-on-one meetings via video calls during the summit. Artelo focuses on developing therapeutics targeting the endocannabinoid system for conditions like anorexia, cancer, and pain. For details, visit www.artelobio.com.

Artelo Biosciences (NASDAQ: ARTL) recently announced the closing of a $7.6 million underwritten public offering and received ethics approval for the CAReS study of ART27.13 in the UK. The company expanded its exclusive worldwide license with Stony Brook University for the FABP5 inhibitor platform aimed at treating cancer, pain, and inflammation. For the fiscal year ending August 31, 2020, Artelo reported a net loss of $4.65 million or $1.26 per share, an increase from the previous year, and had cash reserves of approximately $2.14 million.

Artelo Biosciences (NASDAQ: ARTL) has announced a significant advance in the treatment of psychological disorders, filing a patent for FABP5 inhibitors aimed at conditions like anxiety and PTSD. Recent preclinical data indicate that inhibiting FABP5 increases anandamide levels in critical brain regions, potentially providing a new therapeutic pathway with fewer side effects compared to current treatments. This is particularly relevant as COVID-19 may heighten PTSD risks. The company has also expanded its patent estate by acquiring rights to third-generation FABP5 inhibitors.

Artelo Biosciences (NASDAQ: ARTL) announced the closing of an underwritten public offering, raising approximately $7.6 million. The offering consisted of 10,120,000 units, each priced at $0.75, including common stock and warrants with the same exercise price expiring after five years. This offering included the full exercise of the underwriter's over-allotment option. Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager. The issuance was registered under SEC Form S-1 effective October 8, 2020.

Artelo Biosciences, Inc. (NASDAQ: ARTL) announced an underwritten public offering, aiming for gross proceeds of approximately $6.6 million. The offering includes 8.8 million units priced at $0.75 per unit, each unit consisting of one share of common stock and a warrant with an identical exercise price, expiring in five years. The closing is anticipated on or around October 14, 2020. Additionally, underwriters have a 45-day option to purchase up to 1.32 million additional shares and warrants for over-allotments. This offering follows SEC registration (File No. 333-249083) approved on October 8, 2020.

Artelo Biosciences, Inc. (NASDAQ: ARTL) announced its participation in the H.C. Wainwright Annual Global Investment Conference, taking place virtually from September 14-16, 2020. CEO Gregory D. Gorgas is set to present on September 15 at 3:30 p.m. Eastern Time, with a live webcast available on the event platform. The company focuses on developing therapeutics targeting the endocannabinoid system to address unmet medical needs in various conditions such as cancer, pain, and anorexia. More details can be found on their website.

Artelo Biosciences, Inc. (NASDAQ: ARTL) will participate in the 3rd Annual International Cannabinoid Derived Pharmaceuticals Summit from September 15-17, 2020. CEO Gregory D. Gorgas will discuss intellectual property strategies for cannabinoid drug development on September 15, while Interim CSO Andy Yates, PhD, will present on clinical trial design and the ART27.13 program for cancer-related anorexia on September 16. This summit aims to address challenges in cannabinoid pharmaceutical development, fostering critical discussions among industry specialists.

Artelo Biosciences, Inc. (NASDAQ:ARTL) will present at the LD 500 Virtual Investor Conference from September 1-4, 2020. CEO Gregory D. Gorgas is scheduled to speak on September 1 at 10:20 a.m. Eastern Time. The presentation will be available via webcast. Artelo is focused on developing therapeutics targeting the endocannabinoid system for conditions like cancer and pain. Attendees can schedule one-on-one meetings with the company through the conference registration platform.